A First-in-Human, Phase 1a/b, Dose-Escalation/Expansion Study of BG-68501, a Selective CDK2 Inhibitor, as Monotherapy or in Combination With Fulvestrant for Patients With HR+/HER2– Breast Cancer and Other Advanced Solid Tumors: First Disclosure of Clinical Data

Brian A. Van Tine, MD, PhD, presents results from the first-in-human Phase 1a trial of BG-68501, a selective CDK2 inhibitor, showing early signs of antitumor activity and a manageable safety profile in heavily pretreated patients with advanced solid tumors, including HR+/HER2– breast cancer and ovarian cancer, supporting continued dose escalation and ongoing enrollment.

Related Content:

Rapid Readouts

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study

Lurbinectedin + Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Results of the Phase 3 IMforte Trial

ARCHES: 5-Year Follow-up Overall Survival (OS) Analysis of Enzalutamide (ENZA) Plus Androgen-Deprivation Therapy (ADT) in Patients (pts) With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)